ArticleCancer2018

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Amir T Fathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.